Follistatin 344 vs IGF-1 LR3

Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Follistatin-344 is the predominant endogenous isoform of follistatin, a glycoprotein that binds and neutralizes the TGF-β superfamily members activin A and myostatin, preventing their engagement with skeletal muscle ActRII receptors and thereby relieving their inhibitory effects on muscle protein synthesis and satellite cell activation. By sequestering both myostatin and activin A simultaneously, follistatin-344 neutralizes two complementary negative regulators of muscle growth through a dual-pathway mechanism, a property that distinguishes it from agents that target only the myostatin pathway. Transgenic expression of human follistatin-344 has produced significant skeletal muscle mass increases in animal models, and a phase 1/2a gene therapy trial delivering the follistatin-344 gene via AAV to patients with Becker muscular dystrophy established initial proof of concept and safety data in a human clinical context. Follistatin-344 has not received FDA approval for any indication; exogenous administration as a recombinant protein or peptide is investigational and no human safety data exists for this route of administration outside gene therapy trial contexts. Follistatin-344 as a research compound: recombinant follistatin-344 protein is available through research biochemical suppliers as a laboratory reagent, used in cell culture and animal models to probe myostatin and activin A biology. Interest in exogenous follistatin-344 administration in performance contexts has grown from the animal model hypertrophy data; however, the protein's large molecular weight (~35 kDa glycoprotein) creates significant bioavailability challenges for subcutaneous or intramuscular routes, and no human pharmacokinetic data supports assumed tissue distribution from injection. This distinguishes it from smaller peptide-based myostatin modulators. Follistatin-344 vs myostatin propeptide: both target myostatin inhibition but through different binding mechanisms. Follistatin-344 binds activin A in addition to myostatin, providing a broader TGF-β inhibition profile. Myostatin propeptide is the endogenous inhibitory domain of the myostatin precursor protein — it is myostatin-specific but structurally derived from the same protein rather than from a binding antagonist class. Both compounds remain at the research stage for performance applications with no approved human use. Providers offering research peptides in the performance and muscle recovery category are listed in the PeptideBase directory.

Long-acting analog of IGF-1 that binds to IGF-1 receptors, promoting muscle protein synthesis, cellular growth, and recovery. Suppresses myostatin activity and has a significantly extended half-life compared to native IGF-1 due to reduced binding protein affinity.

IGF-1-LR3 (Long Arg3 IGF-1) is a synthetic 83-amino-acid analog of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that substantially reduces binding to IGF-binding proteins (IGFBPs), resulting in a biological half-life approximately 120 times longer than native IGF-1 and theoretically greater receptor availability in peripheral tissues. The reduced IGFBP affinity means a higher proportion of circulating IGF-1-LR3 remains unbound and potentially bioactive; in vitro cell proliferation studies and animal models suggest amplified anabolic signaling relative to equimolar native IGF-1, and the compound is widely used as a research reagent in cell culture for controlled IGF-1R stimulation without the confounding effects of endogenous binding protein dynamics. No human pharmacokinetic, safety, or efficacy studies of IGF-1-LR3 have been published in PubMed-indexed journals; the indexed scientific literature consists of in vitro proliferation studies, animal metabolic research, and anti-doping detection methods — a complete absence of clinical data supporting or characterizing its use in humans. IGF-1-LR3 has no FDA approval or regulatory approval in any jurisdiction; it is a research laboratory reagent and non-approved analog available through research chemical suppliers, and the complete absence of published human data means its pharmacological behavior, tissue distribution, and safety profile in humans are entirely uncharacterized. IGF-1 LR3 in research contexts: as a laboratory reagent, IGF-1-LR3 is used at nanomolar concentrations in cell culture assays to stimulate IGF-1 receptor signaling. The extended half-life (approximately 20–30 hours compared to native IGF-1's 15 minutes) is the primary reason for its use in research settings requiring sustained IGF-1R activation. In animal pharmacology studies, doses vary widely by species and model; these cannot be directly extrapolated to human dosing, and no safe or effective human dose has been established. Its extended half-life relative to native IGF-1 is also the property most frequently cited in anti-doping detection literature, where the compound has been identified in biological samples from competitive athletes. The absence of any human clinical data distinguishes IGF-1-LR3 from growth hormone secretagogues such as sermorelin, ipamorelin, or MK-677, which have documented human pharmacological profiles. Providers offering researched GH-axis peptides with clinical datasets are listed in the PeptideBase directory.